News

All of Ferrer’s information, just a click away

normal

Improving clinical research for people with Cyclic Vomiting Syndrome (CVS), the new challenge from Ferrer 4 Future for the entrepreneurial ecosystem

.

Wed, 05/11/2022 - 14:21

Ferrer brings the first PHantasticals to life to raise awareness of Pulmonary Hypertension

.

Thu, 05/05/2022 - 08:21

Ferrer, strategic partner of Barcelona+B, the initiative to promote a more prosperous, sustainable and inclusive city

.

Wed, 04/27/2022 - 09:05

More than 400 employees from Ferrer take part in a social initiative in Spain

.

Fri, 04/08/2022 - 10:34

Ferrer, the first pharmaceutical company committed to recovering waste medicines in Costa Rica

.

Wed, 03/23/2022 - 17:51

Details of Clinical Trial ADORE for Amyotrophic Lateral Sclerosis (ALS)

.

Thu, 02/24/2022 - 09:17

Ferrer announces distribution agreement with United Therapeutics for treprostinil inhalation solution for pulmonary hypertension associated with interstitial lung disease

.

Wed, 02/23/2022 - 15:24

Ferrer becomes a B Corp for its positive impact in society

.

Tue, 01/25/2022 - 15:06

Ferrer joins Barcelona + B, a project to bring the business community closer to the SDGs

.

Mon, 11/29/2021 - 17:47

First patient enrolled in Ferrer's FNP122 ADORE Phase III clinical trial for Amyotrophic Lateral Sclerosis (ALS) treatment

.

Mon, 11/08/2021 - 14:12

For requests for interviews or information, please contact the Communications Department

alternatively, please dial +34 936 003 779

See more

Business Development